Artificial intelligence drives the identification and screening of novel antibiotics and antimicrobial peptides.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41978380.
- Also identified by DOI 10.1093/bib/bbag107 and PMC identifier 13076943.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The discovery of new antimicrobial drugs has become urgent due to the growing threat of antimicrobial resistance in the 21st century. However, high-throughput screening is costly and time-consuming. Artificial intelligence (AI) can facilitate the discovery of novel antibiotics and antimicrobial peptides (AMPs) by accelerating identification and reducing development costs. This review focuses on the application of artificial intelligence in the discovery of novel antibiotics and AMPs, highlighting recent advances and practical strategies in AI-driven antibacterial drug development. Ultimately, this article aims to provide practical support and guidance for researchers in antimicrobial discovery, thereby contributing to resolving the global health crisis.
Medical subject headings
- Artificial Intelligence
- Anti-Bacterial Agents
- Antimicrobial Peptides
- Drug Discovery